Top in allergy/asthma: Passing of Marcus Maurer, MD; briquilimab for chronic urticaria
The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine in Berlin, who is remembered for his excellent teaching and scientific achievements.
“He was just the most charismatic person I ever met... He taught me about the fact, never, there is never a problem, but always issues and challenges,” Francesca Levi-Schaffer, PharmD, PhD, FRCP (Hon), professor at the Hebrew University of Jerusalem Institute for Drug Research, who worked with Maurer for 20 years, told Healio. “Also, he knew how to speak science in a layperson language and [was] so extremely communicative.”
Maurer’s work will carry on, Levi-Schaffer said.
It was the top story in allergy/asthma last week.
In another top story, results from the randomized BEACON trial revealed that adults with moderate to severe chronic spontaneous urticaria saw substantial reductions in tryptase as early as week 1 with briquilimab.
The researchers noted that 100% of patients with a single 240 mg dose achieved complete response at week 8.
Read these and more top stories in allergy/asthma below:
Allergy, immunology mourns the loss of Marcus Maurer, MD
Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin. Read more.
Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab
Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 weeks of treatment, with responses as early as week 1, according to an online presentation by Jasper Therapeutics. Read more.
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
As wildfires continue to spread across the Los Angeles area, residents with asthma and other respiratory diseases face increased risks to their health. Read more.
Lanadelumab increases attack-free rates in hereditary angioedema patients
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Gestational diabetes, asthma link highlights need for early screening in pregnant women
Gestational diabetes led to an increased risk for asthma exacerbations during pregnancy among a group of women with pre-existing asthma, according to results of a retrospective cohort study. Read more.